Medium spiny neurons (MSNs) are the principal neurons of the striatum (caudate nucleus and putamen), comprising approximately 95% of striatal neurons. Named for their medium-sized cell bodies (~12-20 μm) and spiny dendrites, they are GABAergic projection neurons that form the primary output pathway of the basal ganglia. Degeneration of MSNs is the hallmark of Huntington's disease, making them critical to understanding movement disorders and basal ganglia circuit dysfunction.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:1001474 | medium spiny neuron |
The striatum is the largest component of the basal ganglia:
Soma: 12-20 μm diameter, relatively small compared to cortical pyramidal cells
Dendrites:
Axon:
| Source | Neurotransmitter | Target |
|---|---|---|
| Cerebral cortex (all layers) | Glutamate | MSN spines (major excitatory) |
| Thalamus (intralaminar nuclei) | Glutamate | MSN spines |
| Substantia nigra pars compacta | Dopamine | MSN spines/shaft |
| Raphe nuclei | Serotonin | MSN dendrites |
| Basal forebrain | Acetylcholine | Interneurons (indirect) |
The fundamental division of MSNs is based on dopamine receptor expression:
D1-Expressing MSNs (Direct Pathway)
D2-Expressing MSNs (Indirect Pathway)
Glutamic acid decarboxylase (GAD67/GAD1, GAD65/GAD2):
Vesicular GABA Transporter (VGAT/SLC32A1):
Key transcription factors in MSN specification:
Dopamine- and cAMP-regulated phosphoprotein, 32 kDa:
MSNs exhibit bistable membrane potential states:
Down State:
Up State:
Cortex → Striatum (D1-MSN) → GPi/SNr → Thalamus → Cortex
| |
| (GABA) | (GABA)
+--------------------+
DISINHIBITS
Cortex → Striatum (D2-MSN) → GPe → STN → GPi/SNr → Thalamus → Cortex
| | | |
| (GABA) |(GABA)|(GLU) | (GABA)
+---------------+------+------+----------+
NET INHIBITION
Normal motor control requires balanced direct/indirect pathway activity:
Huntington's disease (HD) shows characteristic selective vulnerability:
Early stages:
Later stages:
Explanation: D2-MSNs may have lower neuroprotective BDNF signaling or higher metabolic stress[6]
Huntingtin protein (HTT):
Cellular effects:
| Pathway | Normal Function | HD Change |
|---|---|---|
| Dopamine | Motor control | Enhanced D1 signaling, early hypersensitivity |
| BDNF | MSN survival | Reduced cortical transport, TrkB downregulation |
| mTOR | Protein synthesis | Dysregulated |
| Autophagy | Protein clearance | Impaired |
Chorea:
Motor symptoms:
| Strategy | Target | Status |
|---|---|---|
| Gene silencing | HTT mRNA | Phase III trials (tominersen discontinued, ongoing with others) |
| BDNF enhancement | TrkB agonists | Preclinical |
| Autophagy enhancement | mTOR inhibition | Preclinical/early trials |
| CRISPR editing | CAG repeat | Preclinical |
Cell replacement:
Deep brain stimulation:
| Model | Features | Use |
|---|---|---|
| R6/2 transgenic | Aggressive HD phenotype | Rapid drug screening |
| YAC128 | Slower progression | Pathophysiology |
| Q175 knock-in | More physiological | Therapeutic testing |
| QA lesion | Excitotoxic MSN loss | Cell replacement studies |
BrainSpan - Medium Spiny Neurons Developmental Transcriptome
Neurons Major brain cell type
Glia — Suppor- Alzheimer's DiseaseAlzhe- Parkinson's Diseased neurodegenerative disease
Parkinson's Disease Related neurodegenerative disease
This cell type belongs to the GABAergic class, specifically the Striatal medium spiny neuron subclass in the BICAN (Brain Initiative Cell Atlas Network) taxonomy.
The BICAN taxonomy provides a standardized classification of cell types across species, enabling cross-species comparisons of neuronal and glial cell populations.
Cell Ontology terms for this cell type:
This cell type shows varying degrees of conservation across model organisms:
| Species | Conservation Level | Key Differences |
|---|---|---|
| Mouse | High | Slight differences in layer-specific markers |
| Human | Reference | Larger cell bodies, more complex dendritic arborization |
| Macaque | High | Similar to human, minor morphological variations |
| Zebra finch | Moderate | Species-specific song circuit specialization |
Lobo MK, et al. Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science. 2010. ↩︎
Vernay A, et al. Foxp1 mutation in a new form of basal ganglia disease. Brain. 2018. ↩︎
Arlotta P, et al. Ctip2 controls the differentiation of medium spiny neurons and the establishment of the cellular architecture of the striatum. J Neurosci. 2008. ↩︎
Svenningsson P, et al. DARPP-32: An integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004. ↩︎
Wilson CJ, et al. Up states, down states, and the cortical-pallidal loops. Parkinsonism Relat Disord. 2007. ↩︎
Reiner A, et al. The group of striatal projection neurons with large dendritic fields in the pigeon. J Comp Neurol. 2005. ↩︎